Rating is available when the video has been rented.
This feature is not available right now. Please try again later.
Published on Apr 19, 2010
Dr. Suresh Ramalingam on the details of a phase three trial of the drug crizotinib for treatment of a specific type of non-small cell lung cancer. The treatment would either be in addition or possibly as a replacement for chemotherapy. Ramalingam is with the Winship Cancer Institute of Emory University, one of the sites of a national research trial. Trial sponsor is the drug's producer, Pfizer.
About Dr. Suresh Ramalingam Suresh Ramalingam, MD, is an Associate Professor, Winship Cancer Institute, Emory University School of Medicine. He is also Director, Medical Oncology Department of Hematology and Medical Oncology.